Filter News
Area of Research
News Topics
- (-) Bioenergy (3)
- (-) Isotopes (1)
- (-) Materials Science (2)
- 3-D Printing/Advanced Manufacturing (6)
- Advanced Reactors (1)
- Big Data (1)
- Biology (1)
- Biomedical (2)
- Biotechnology (2)
- Buildings (2)
- Chemical Sciences (3)
- Climate Change (2)
- Composites (2)
- Computer Science (2)
- Coronavirus (2)
- Decarbonization (5)
- Energy Storage (4)
- Environment (2)
- Grid (2)
- High-Performance Computing (1)
- Machine Learning (1)
- Materials (6)
- Microscopy (1)
- Nanotechnology (1)
- National Security (1)
- Net Zero (1)
- Neutron Science (6)
- Nuclear Energy (3)
- Partnerships (4)
- Physics (1)
- Renewable Energy (1)
- Security (1)
- Simulation (1)
- Summit (1)
- Sustainable Energy (1)
- Transportation (4)
Media Contacts
Four scientists affiliated with ORNL were named Battelle Distinguished Inventors during the lab’s annual Innovation Awards on Dec. 1 in recognition of being granted 14 or more United States patents.
ORNL has entered a strategic research partnership with the United Kingdom Atomic Energy Authority, or UKAEA, to investigate how different types of materials behave under the influence of high-energy neutron sources. The $4 million project is part of UKAEA's roadmap program, which aims to produce electricity from fusion.
Scientists at the Department of Energy’s Oak Ridge National Laboratory have created a recipe for a renewable 3D printing feedstock that could spur a profitable new use for an intractable biorefinery byproduct: lignin.
Scientists studying a valuable, but vulnerable, species of poplar have identified the genetic mechanism responsible for the species’ inability to resist a pervasive and deadly disease. Their finding, published in the Proceedings of the National Academy of Sciences, could lead to more successful hybrid poplar varieties for increased biofuels and forestry production and protect native trees against infection.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.